Efficacy and safety of febuxostat in renal transplant recipients with hyperuricemia
10.3760/cma.j.issn.0254-1785.2019.03.008
- VernacularTitle:非布司他治疗肾移植后高尿酸血症的有效性和安全性
- Author:
Jiajia JIANG
1
;
Qian FU
;
Sizhe LONG
;
Huanxi ZHANG
;
Xiaojun SU
;
Jun LI
;
Chenglin WU
;
Ronghai DENG
;
Longshan LIU
;
Wujun ZHANG
;
Changxi WANG
Author Information
1. 中山大学附属第一医院器官移植中心
- Keywords:
Renal transplantation;
Hyperuricemia;
Efficacy
- From:
Chinese Journal of Organ Transplantation
2019;40(3):158-161
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of febuxostat in the treatment of hypemricemia in renal transplant recipients.Methods A total of 124 renal transplant patients with hyperuricemia receiving febuxostat between June 2016 and July 2018 were retrospectively analyzed.Uric acid (UA),liver function and renal function parameters before and 3 months after treatment were compared.Adverse events,recipient and renal allograft survival were recorded throughout the follow-up period.Results Serum level of uric acid significantly decreased after 3-month treatment (P＜0.001).And 66.1％ of them achieved target UA level at Month 3 after dosing.Estimated glomerular filtration rate (eGFR) was maintained.No severe adverse event was observed.All recipient and renal grafts survived during the follow-up period.Conclusions Febuxostat is both effective and safe in the treatment of hyperuricemia in renal transplant.
